Dextran carrier macromolecule for colon specific delivery of celecoxib

Current Drug Delivery

Volumn 7, Issue 2, 2010, Pages 144-151

  Shrivastava, Prabhat K ^a   Shrivastava, Sushant K ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Celecoxib; Colon specificity; Dextran; In vitro hydrolysis

Indexed keywords

CELECOXIB; DEXTRAN; SUCCINIC ACID;

ANIMAL TISSUE; ARTICLE; CECUM; COLON; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG HYDROLYSIS; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOGENATE; IN VITRO STUDY; IRRADIATION; MACROMOLECULE; MALE; MOLECULAR WEIGHT; NONHUMAN; PH; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SMALL INTESTINE; STOMACH JUICE; SUBSTITUTION REACTION; ULTRAVIOLET RADIATION;

EID: 77950795458     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720110791011828     Document Type: Article

References (33)

1. World health organization. Global burden of cancer. http://www.who.int/ mediacentre/factsheets/fs297/en/[Accessed on 18 Aug 2009].
2. Marnett, L.J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 1992, 52, 5575-5589.
3. Giardiello, F.M.; Hamilton, S.R.; Krush, A.J.; Piantadosi, S.; Hylind, L.M.; Celano, P. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 1993, 328, 1313-1316. (Pubitemid 23131373)
4. Ahnen, D.J. Colon cancer prevention by NSAIDs: What is the mechanism of action? Eur. J. Surg. Suppl., 1998, 582, 111-114.
5. Marnett, L.J.; DuBois, R.N. COX-2: A Target for colon cancer prevention. Annu. Rev. Pharmacol. Toxicol., 2002, 42, 55-80.
6. Reddy, B.S.; Hirose, Y.; Lubet, R.; Steele, V.; Kelloff, G.; Paulson, S.; Seibert, K.; Rao, C.V. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res., 2000, 60, 293-297.
7. Reddy, B.S.; Patlolla, J.M.; Simi, B.; Wang, S.H.; Rao, C.V. Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in ω-3 polyunsaturated fatty acids. Cancer Res., 2005, 65, 8022-8027.
8. Kawamori, T.; Rao, C.V.; Seibert, K.; Reddy, B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 1998, 58(3), 409-412.
9. Gaurel, A.; Martel A.M.; Castaner, J. Celecoxib, anti-inflammatory, cyclo-oxygenase-2 inhibitor. Drugs Future, 1997, 22, 711-714.
10. Mukherjee, D.; Nissen, S.E.; Topol, E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001, 286, 954-959. (Pubitemid 33010342)
11. Krishnaiah, Y.S.R.; Satyanarayana, S.; Kumar, B.D.; Karthikeyan, R.S. Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer. J. Drug. Target., 2002, http://www.informaworld.com/smpp/title~content=t713640314~db=all~tab= issueslist~branches=10 - v1010(3), 247-254.
12. Mrnsy, R.J. The colon as a site for drug delivery. J. Control. Release, 1992, 22, 15-34.
13. Simon, G.I.; Gorbach, S.L. The human intestinal microflora. Dig. Dis. Sci., 1986, 31, 147S-162S.
14. Chourasia, M.K.; Jain, S.K. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci., 2003, 6, 33-66.
15. Sinha, V.R.; Kumria, R. Colon drug delivery: Prodrug approach. Pharm. Res., 2001, 53, 41-47.
16. Hovgaard, L.; Brondsted, H. Current applications of polysaccharides in colon targeting. Crit. Rev. Ther. Drug. Carrier Syst., 1996, 13, 185-223. (Pubitemid 27024257)
17. Kaur, K.; Kim, K. Studies of chitosan/organic acid/Eudragit® RS/RL-coated system for colonic delivery. Int. J. Pharm., 2009, 366, 140-148.
18. Lee, H.K.; Lambert, H.; Stella, V.J.; Wang, D.; Higuchi, T. Hydrolysis and dissolution behavior of a prolonged-release prodrug of theophylline: 7, 7' -Succinylditheophylline. J. Pharm. Sci., 1979, 68, 288-295.
19. Akiko, I.; Hirofumi, I.; Takashi, S. Inhibitory effect of succinic acid on epithelial cell proliferation of colonic mucosa in rats. J. Nutr. Sci. Vitaminol., 2007, 53(4), 377-379. (Pubitemid 47442360)
20. Larsen, C.; Harboe, E.; Johansen, M.; Olesen, H.P. Macromolecular prodrugs. XVI. Colon-targeted delivery-comparison of the rate of release of naproxen from dextran ester prodrugs in homogenates of various segments of the pig gastrointestinal tract. Pharm. Res., 1989, 6, 995-999.
21. Lee, J.S.; Jung, Y.J.; Doh, M.J.; Kim, Y.M. Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid. Drug Dev. Ind. Pharm., 2001, 27(4), 331-336.
22. Ahmad, S.; Tester, R.F.; Corbett, A.; Karkalas, J. Dextran and 5-aminosalicylic acid (5-ASA) conjugates: synthesis, characterization and enzymic hydrolysis. Carbohydr. Res., 2006, 341, 2694-2701.
23. McLeod, A.D.; Friend, D.R.; Tozer, T.N. Synthesis and chemical stability of glucocorticoid-dextran esters: potential prodrugs for colon-specific delivery. Int. J. Pharm., 1993, 92, 105-114.
24. Vaidya. A.A.; Lele, B.S.; Kulkarni, M.G.; Mashelkar, R.A. Enhancing ligand-protein binding in affinity thermo precipitation: elucidation of spacer effects. Biotechnol. Bioeng., 1999, 64, 418-425.
25. Shrivastava, S.K.; Jain, D.K.; Trivedi, P. Dextrans - potential polymeric drug carriers for flurbiprofen. Pharmazie, 2003, 58, 389-391. (Pubitemid 36733846)
26. De-Belder, A.N.; Norman, B. The distribution of substituents in partially acetylated dextran, Carbohydr. Res., 1968, 8, 1.
27. Khan, Z.; Zeljko, P.; Nevenka, K. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit® L100-55 and Eudragit® S100 combinations. J. Control. Release, 1999, 58, 215-222.
28. Gang, C.; Feng, A.; Mei-Juan, Z.; Jin, S. Time and pH-dependent colon-specific drug delivery for orally administered diclofenac sodium and 5-amino salicylic acid. World J. Gastroenterol., 2004, 10, 1769-1774.
29. Sinha, V.R.; Kumria, R. Microbially triggered drug delivery to the colon. Eur. J. Pharm. Sci., 2003, 18, 3-18. (Pubitemid 36120550)
30. th ed.; Mack Publishing Company: Easton, Pennsylvania, 1995.
31. Bajpai, S.K.; Bajpai, M.; Dengree, R. chemically treated hard gelatin capsules for colon-targeted drug delivery: a novel approach. J. Appl. Polym. Sci., 2003, 89, 2277-2282.
32. Sinha, V.R.; Kumria, R. Polysaccharides in colon-specific drug delivery. Int. J. Pharm., 2001, 224, 19-38.
33. Dhaneshwar, S.S.; Chaila, M.; Patila, M.; Naqvib, S.; Vadnerkar, G. Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats. Eur. J. Med. Chem., 2009, 44(1), 131-142.